Oppenheimer ‘not writing off’ Fulcrum Therapeutics’ 6058 ‘just yet’

After Fulcrum Therapeutics hosted a call along with Q4 earnings and provided additional details on FTX-6058’s clinical hold, Oppenheimer noted that the company disclosed that the hold was related to the emergence of hematological malignancies in preclinical model, which the firm had thought "was the most likely scenario." The question "effectively becomes whether the benefits outweigh the risks" and the firm thinks they may, adding that the updated data shared on the call bolsters that view. Oppenheimer, which said its "not writing off ‘6058 just yet," reiterates an Outperform rating and $20 price target on Fulcrum shares.